Effects of vaccine in treatment of Hepatitis b patients
Phase 3
- Conditions
- Hepatitis B virus carrier.Hepatitis B surface antigen [HBsAg] carrier
- Registration Number
- IRCT201202259124N1
- Lead Sponsor
- Vice chancellor for research, Golestan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
Age between 20 and 65 years; Absence of clinical manifestations of hepatitis B infection; ALT=<40
Exclusion criteria: ALT>40; Presence of clinical manifestations of hepatitis B infection
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method HBV viral load. Timepoint: Before firt dose of vaccine and 1 month after last dose of vaccine. Method of measurement: Real time PCR of serum samples.
- Secondary Outcome Measures
Name Time Method evels of ALT. Timepoint: Start of the study; months 2 and 7. Method of measurement: Serologic examination.